The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with survival rates exceeding 85%. However, 15% of patients will relapse; consequently, their survival rates decrease to below 50%. Therefore, several research and innovation studies are focusing on pediatric relapsed or refractory ALL (R/R ALL). Driven by this context and following the European strategic plan to implement precision medicine equitably, the Relapsed ALL Network (ReALLNet) was launched under the umbrella of SEHOP in 2021, aiming to connect bedside patient care with expert groups in R/R ALL in an interdisciplinary and multicentric network. To achieve this objective, a board consisting of experts in diagnosis, management, preclinical research, and clinical trials has been established. The requirements of treatment centers have been evaluated, and the available oncogenomic and functional study resources have been assessed and organized. A shipping platform has been developed to process samples requiring study derivation, and an integrated diagnostic committee has been established to report results. These biological data, as well as patient outcomes, are collected in a national registry. Additionally, samples from all patients are stored in a biobank. This comprehensive repository of data and samples is expected to foster an environment where preclinical researchers and data scientists can seek to meet the complex needs of this challenging population. This proof of concept aims to demonstrate that a network-based organization, such as that embodied by ReALLNet, provides the ideal niche for the equitable and efficient implementation of “what's next” in the management of children with R/R ALL.

[1]  A. Trifa,et al.  Addressing the unmet need for a comprehensive lung cancer registry in Romania , 2023, Frontiers in Oncology.

[2]  A. Letai,et al.  BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia , 2023, Blood advances.

[3]  A. Borkhardt,et al.  Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants , 2022, Leukemia.

[4]  J. Samitier,et al.  MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia , 2021, Frontiers in Cell and Developmental Biology.

[5]  David C. Jones,et al.  The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets , 2021, Cancer discovery.

[6]  T. Révész,et al.  Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. , 2021, European journal of cancer.

[7]  S. Rives,et al.  Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia , 2021, Clinical and Translational Oncology.

[8]  D. Steinemann,et al.  Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome , 2021, Leukemia.

[9]  S. Rives,et al.  Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) , 2020, British journal of haematology.

[10]  S. Rives,et al.  ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain , 2019, Clinical and Translational Oncology.

[11]  Julian M. Hess,et al.  Passenger Hotspot Mutations in Cancer , 2019, bioRxiv.

[12]  M. Norkin,et al.  A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. , 2019, Blood advances.

[13]  S. Rives,et al.  Impact of polymorphisms in apoptosis‐related genes on the outcome of childhood acute lymphoblastic leukaemia , 2018, British journal of haematology.

[14]  Annette S. Kim,et al.  Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium , 2018, Blood.

[15]  S. Méndez-Ferrer,et al.  Myeloid malignancies and the microenvironment. , 2017, Blood.

[16]  C. Porter Germ line mutations associated with leukemias. , 2016, Hematology. American Society of Hematology. Education Program.

[17]  M. D. Den Boer,et al.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. , 2016, Blood.

[18]  F. Supek,et al.  MUFFINN: cancer gene discovery via network analysis of somatic mutation data , 2016, Genome Biology.

[19]  Y. Saeys,et al.  Computational flow cytometry: helping to make sense of high-dimensional immunology data , 2016, Nature Reviews Immunology.

[20]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[21]  T. Aittokallio,et al.  JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. , 2015, Blood.

[22]  A. Letai,et al.  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. , 2015, Cancer cell.

[23]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[24]  Arndt Borkhardt,et al.  Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Julia C. Engelmann,et al.  Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia , 2013, Leukemia.

[26]  C. Pui,et al.  Outcomes after induction failure in childhood acute lymphoblastic leukemia. , 2012, The New England journal of medicine.

[27]  M. Loh,et al.  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[29]  E. Cook,et al.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.